我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

氨氯地平联合替米沙坦及复方盐酸阿米洛利治疗高血压和左室肥厚的效果及其与瘦素的关系

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2009年第3期
页码:
367-370,374
栏目:
临床研究
出版日期:
2009-05-15

文章信息/Info

Title:
Effects of amlodipine association telmisartan and amilorid in the treatment of high blood pressure and left ventricular hypertrophy and its relationship with leptin
作者:
景晓娟1; 赵连友1; 章燕2; 薛玉生1; 侯小玲1; 艾永飞1; 田刚3; 何争4; 张军4
第四军医大学：1.唐都医院心内科，陕西 西安 710038，2.生物医学工程系医学电子工程学教研室，陕西 西安 710032，4.西京医院心内科,陕西 西安 710032；3.西安交通大学第一附属医院心内科，陕西 西安 710061
Author(s):
JING Xiao-juan1;  ZHAO Lian-you1;  ZHANG Yan2;  XUE Yu-sheng1;  HOU Xiao-ling1;  AI Yong-fei1;  TIAN Gang3;  HE Zheng4;  ZHANG Jun4
1.Department of Cardiology, Tangdu Hospital, Xi’an 710038, China, 2.Department of Biomedical Engineering, Faculaty of Biomedical Engineering, 4.Department of Cardiology, Xijing Hospital, Fourth Military Medical University, Xi’an 710032, Shaanxi, China; 3
关键词:
降压药; 左心室肥厚; 左室质量指数; 瘦素
Keywords:
hypotensor;  left ventricular hypertrophy;  left ventricular weight index;  leptin
分类号:
R544.1
DOI:
-
文献标识码:
A
摘要:
目的 比较氨氯地平联合应用替米沙坦（氨+替组）及氨氯地平联合应用复方盐酸阿米洛利（氨+阿组）对高血压患者血压及左室肥厚（LVH）的影响，并探讨血压和左室肥厚与血清瘦素水平的关系。方法 将确诊的92例LVH患者随机分配到氨+替组（46例）和氨+阿组（46例）。治疗半年后，观察两组患者心脏形态学、心脏功能及血清瘦素水平的变化。结果 氨+替组及氨+阿组患者经过治疗后，收缩压、舒张压、室间隔厚度、左室质量、左室质量指数及血清瘦素水平与治疗前比较，均有显著降低（均P<0.01），E/A比值及EF值与治疗前比较有显著增高（P<0.05），但两组间治疗后收缩压、舒张压差别无统计学意义，余均有显著改变（P<0.05），氨+替组作用更明显。结论 氨+替组有更好的降压、保护心脏的效果。瘦素参与了左心室肥厚的发生、发展，可作为观察高血压患者病情变化的指标。
Abstract:
AIM To compare the application of amlodipine united telmisartan and amlodipine combination amiloride on blood pressure in patients with hypertension and left ventricular hypertrophy, and explore the left ventricular hypertrophy(LVH) and the relationship between serum leptin level. METHODS 92 cases of diagnosed LVH were randomly assigned to amlodipine+amiloride group (46 cases) or amlodipine+telmisartan group (46 cases). Six months after treatment, cardiac morphology, cardiac function and serum leptin level changes were observed in patients. RESULTS Amlodipine + amiloride group and amlodipine+telmisartan group of patients after treatment, systolic blood pressure, diastolic blood pressure, ventricular septal thickness, left ventricular mass, left ventricular mass index, E/A ratio, EF values and serum leptin levels were significantly change (P<0.01 or P<0.05), but between the two groups after treatment systolic pressure, diastolic blood pressure difference was not statistically significant, more than all the differences (P<0.05). CONCLUSION The two groups were significantly lower blood pressure, reverse left ventricular hypertrophy and improve cardiac function and reduce the role of serum leptin level, but the role of amlodipine+telmisartan group even more obvious. Tips for group amlodipine+telmisartan has a better treatment of hypertension, the effectiveness of the protection of the heart and prompt leptin involved in the occurrence of left ventricular hypertrophy, development, and that leptin can be used as observation of changes in hypertensive patients with target.

参考文献/References

[1］ Mathew J, Sleight P, Lonn E, et al. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by angiotension converting enzyme inhibitor ramipril［J］. Circulation, 2001, 104(14):1615-1621.

［2］ Palmieri V, Devereux RB. Angiotension converting enzyme inhibition and dihydropyridine calcium channel blockade in the treatment of left ventricular hypertrophy in arterial hypertension［J］. Minerva Cardioangiology, 2002, 50(3):169-174.

［3］ Gosse P, Sheridan DJ, Zannad F, et al. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus enalapril 20 mg: the LIVE study［J］. J Hypertens, 2000, 18(10):1465-1475.

［4］ Devereux RB, Alonso BR, Lutes EM, et al. Echocardiography assessment of left vent ricular hypertrophy: comparison to necropsy findigs［J］. Am J Cardiol, 1986, 57(6):450-458.

［5］ 王静,段春林. 国人正常左室质量指数的探讨［J］. 中华心血管病杂志, 1996, 24(3):233.

［6］ 林文辉，王齐增，鹏万军，等． 高血压病左室肥厚对房室性心率失常的影响［J］. 心脏杂志, 2008, 20(1):71-73.

［7］ Messerli FH, Ketelhut R. Left ventricular hypertrophy: a pressure-independent cardiovascular risk factor［J］. J ardiovasc Pharmacol, 2003, 22(Suppl):S7-S13．

［8］ Cortrady AO, Rudomanov OG, Zaharov DV, et al. Prospective study of the changes in left ventricular ulags and geometry patterns in hypertensive patients During 5 years of follow up［J］. Circ J, 2005, 69(11):1374-1379．

［9］ Okin PM, Devereux RB, Jern S, et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events［J］. JAMA, 2004, 292(19):2396-2398．

［10］Terpstra WF, May JF, Smit AJ, et al. Long-term efects of Binledipine and lisinopril on left ventricular ulaBs and diastolic function in elderly，previously untreated hypertensive patients： the ELVERA tria1［J］． J Hypertens, 2001, 19(2):303-309．

［11］Oliverio MI, Coffman TM． Anglotensin-II-receptors: new targets for antihypertensive therapy［J］. Clin Cardiol, 1997, 20(1):3-6.

［12］Kizer JR, Dahlf B, Kjeldsen SE, et al. Stroke reduction in hypertensive adults with cardiac hypertrophy randomi zed to losartan versus atenolol:the losartan intervention for endpoint reduction in hypertension study［J］. Hypertension, 2005, 45(1):46-52．

［13］王文，张宇清，马丽媛，等. CHIEF： 中国高血压干预效果研究——初始低剂量钙离子拮抗剂为基础的联合方案治疗高血压的随机临床研究阶段报告-1［J］. 中国循证心血管医学杂志, 2008， 1(1):24-27.

［14］汤永谦,成蓓, 詹浩,等. 男性瘦素水平与原发性高血压左室肥厚的相关性研究［J］. 临床心血管病杂志, 2003, 19(7):392-394.

备注/Memo

备注/Memo:
收稿日期：2009-3-3.基金项目：国家十一五科技支撑计划子课题项目资助（2006BAIO1AO3） 通讯作者：赵连友，教授，主任医师，主要从事高血压发病的分子生物学机制研究Email:zhaolyfmmu@yahoo.com.cn 作者简介：景晓娟,医师,硕士生Email:jingxiaojuangood@163.com
更新日期/Last Update: 2009-05-18